Sparc Technologies, which recently announced the acquisition of Australian company Graphene Technology Solutions (GTS) as well as its plan to become a “significant developer of graphene-based products that will disrupt and transform industrial markets, has established a new graphene bio-medical division aimed at developing non-invasive graphene-based breath sensing devices for detection of diseases in humans and animals.

Sparc will advance the project together with cornerstone shareholder, strategic partner and leading graphene research centre the University of Adelaide (UA) in order to establish and develop non-invasive sensing devices for human and veterinarian applications.

The focus of the project will be research into graphene-based sensing devices for the detection of a selection of volatile organic compounds (VOCs) present in exhaled breath that are understood to be indicators of disease.

Sparc will use graphene's properties with the aim of isolating and identifying a selection of specific compounds which are biomarkers for certain diseases.

Subject to the findings of that work, the project will include development/fabrication of lab-scale sensing devices and initial evaluation of their sensing performances with selected VOCs.

A successful project would provide Sparc with important technology for commercialisation in medical markets.